ATE110277T1 - Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen. - Google Patents

Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.

Info

Publication number
ATE110277T1
ATE110277T1 AT90907817T AT90907817T ATE110277T1 AT E110277 T1 ATE110277 T1 AT E110277T1 AT 90907817 T AT90907817 T AT 90907817T AT 90907817 T AT90907817 T AT 90907817T AT E110277 T1 ATE110277 T1 AT E110277T1
Authority
AT
Austria
Prior art keywords
treatment
motility disorders
medication
manufacture
gnrh analog
Prior art date
Application number
AT90907817T
Other languages
English (en)
Inventor
John R Mathias
Original Assignee
John R Mathias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John R Mathias filed Critical John R Mathias
Application granted granted Critical
Publication of ATE110277T1 publication Critical patent/ATE110277T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT90907817T 1989-05-09 1990-05-03 Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen. ATE110277T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/349,717 US5068221A (en) 1989-05-09 1989-05-09 Treatment of motility disorders with a gnrh analog

Publications (1)

Publication Number Publication Date
ATE110277T1 true ATE110277T1 (de) 1994-09-15

Family

ID=23373648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90907817T ATE110277T1 (de) 1989-05-09 1990-05-03 Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.

Country Status (13)

Country Link
US (1) US5068221A (de)
EP (1) EP0471761B1 (de)
JP (1) JPH04505016A (de)
KR (1) KR920700676A (de)
AT (1) ATE110277T1 (de)
AU (2) AU628763B2 (de)
CA (1) CA2053880C (de)
DE (1) DE69011857T2 (de)
DK (1) DK0471761T3 (de)
ES (1) ES2057565T3 (de)
IL (1) IL94330A (de)
NZ (1) NZ248242A (de)
WO (1) WO1990013308A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434136A (en) * 1990-12-14 1995-07-18 Mathias; John R. Treatment of motility disorders with a GNRH analog
US5470847A (en) * 1993-12-10 1995-11-28 Board Of Regents, The University Of Texas System Ovulation control by regulating nitric oxide levels with arginine derivatives
EP1149843A4 (de) * 1999-01-28 2012-06-06 Chugai Pharmaceutical Co Ltd Substituierte phenethylamin-derivate
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
WO2020097447A1 (en) * 2018-11-09 2020-05-14 Ims Trading, Llc Edible pet chews and methods of forming the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO139560C (no) * 1972-04-29 1979-04-04 Takeda Chemical Industries Ltd Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater
CA1009230A (en) * 1972-09-26 1977-04-26 Daiichi Seiyaku Co. Peptides effecting to the release of sex hormones and a method for preparing the same
JPS563846B2 (de) * 1972-10-12 1981-01-27
AT347054B (de) * 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US4005063A (en) * 1973-10-11 1977-01-25 Abbott Laboratories [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity
US4072668A (en) * 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
US4552764A (en) * 1974-11-14 1985-11-12 Research Corporation Peptides for control of intestinal motility
US4010261A (en) * 1974-11-25 1977-03-01 Abbott Laboratories Method to prevent reproduction with [Des-Gly]10 -GN-RH nonadeptide amide analogs in position
US4002738A (en) * 1975-05-30 1977-01-11 Abbott Laboratories Treatment of specified neoplasias
US4005194A (en) * 1975-06-23 1977-01-25 Abbott Laboratories Treatment of prostatic hyperplasia
US4018914A (en) * 1975-11-13 1977-04-19 Abbott Laboratories Parturition inducement
JPS54148722A (en) * 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
US4409208A (en) * 1980-04-15 1983-10-11 The Salk Institute For Biological Studies GnRH antagonists
US4410514A (en) * 1982-12-06 1983-10-18 The Salk Institute For Biological Studies GnRH Agonists
US4619914A (en) * 1983-03-10 1986-10-28 The Salk Institute For Biological Studies GNRH antagonists IIIB
US4569927A (en) * 1984-02-23 1986-02-11 The Salk Institute For Biological Studies GnRH Antagonists IV
US4652550A (en) * 1984-05-21 1987-03-24 The Salk Institute For Biological Studies GnRH antagonists VII
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
US4752577A (en) * 1984-09-13 1988-06-21 Eli Lilly And Company Method for using a novel transcriptional- and translational-activating sequence in streptomyces
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4740500A (en) * 1985-01-31 1988-04-26 The Salk Institute For Biological Studies GnRH antagonists VIII
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4920102A (en) * 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders

Also Published As

Publication number Publication date
WO1990013308A1 (en) 1990-11-15
CA2053880A1 (en) 1990-11-10
EP0471761A4 (en) 1992-06-24
IL94330A0 (en) 1991-03-10
EP0471761B1 (de) 1994-08-24
IL94330A (en) 1995-03-30
NZ248242A (en) 1997-07-27
DE69011857D1 (de) 1994-09-29
AU5559590A (en) 1990-11-29
US5068221A (en) 1991-11-26
DE69011857T2 (de) 1995-03-23
ES2057565T3 (es) 1994-10-16
AU628763B2 (en) 1992-09-17
DK0471761T3 (da) 1994-09-19
AU1620392A (en) 1992-07-30
CA2053880C (en) 1997-01-14
EP0471761A1 (de) 1992-02-26
AU639403B2 (en) 1993-07-22
KR920700676A (ko) 1992-08-10
JPH04505016A (ja) 1992-09-03

Similar Documents

Publication Publication Date Title
ATE111733T1 (de) Verwendung von nikotin zur herstellung eines kit zur behandlung von krankheitszuständen, die auf eine nikotinbehandlung ansprechen.
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
EP0376251A3 (en) An anticoagulant substance obtained from urine
TW200501978A (en) Use of FGF-18 in the diagnosis and treatment of memory disorders
ATE84877T1 (de) Verfahren zur kristallmorphologischen blut- und harnanalyse, zur fruehdiagnose und zur herstellung von arzneimitteln.
DE69130679D1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
ATE110277T1 (de) Verwendung von gnrh-analog zur herstellung eines arzneimittels zur behandlung von motilitätsstörungen.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
ATE303819T1 (de) Verwendung von langem pentraxin ptx3 zur herstellung eines arzneimittels zur verhütung und heilung von autoimmunkrankheiten
BR9707776A (pt) Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina
KR880002535A (ko) 약제로서의 15-데옥시스퍼구알린의 용도
Machleidt et al. The Chilopa ceremony: A sacrificial ritual for mentally (spiritually) ill patients in a traditional healing centre in Malawi.
Horwitz et al. A case of coronary occlusion followed by pregnancy with successful termination
KR970058708A (ko) 엘-무스콘(l-muscone)의 의약용도
RU93034374A (ru) Лекарственный сбор для лечения ишемической болезни сердца, сопровождающейся выраженными невротическими реакциями
RU2014020C1 (ru) Способ лечения стилоидита
Mascolini HIV and the Mind
Comrie Syringomyelia
Ulanov The comparative clinico-epidemiological characteristics of schizophrenia patients living in urban and rural localities
Burnyasheva et al. On the question of the treatment of urticaria

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee